Pulmonary Fibrosis

Of more than 3,000 lung transplants performed in the U.S. from August 2020 to Sept. 30, 2021, 7% were performed to treat severe, irreversible lung damage caused by COVID-19, researchers reported in The New England Journal of Medicine.

Air pollution has various effects on patients with fibrotic interstitial lung disease, according to preliminary research presented at the PFF Summit.

A speaker at the PFF Summit highlighted recent trials and therapeutic updates for progressive fibrosing interstitial lung disease.

In this Healio Video Perspective from the AWIR Annual Conference, Janet Pope, MD, professor of medicine, epidemiology and biostatistics at Western Bone and Joint Institute in Ontario, Canada, shares three important points from her session on pulmonary arterial hypertension and interstitial lung disease in scleroderma.

Adoption of pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis has been low in the U.S., according to an analysis published in the Annals of the American Thoracic Society.

Treatment with low-dose azithromycin for chronic cough in patients with idiopathic pulmonary fibrosis did not significantly improve cough-related quality of life, severity or frequency compared with placebo.

Age-adjusted mortality rates for idiopathic pulmonary fibrosis decreased from 2004 to 2017 in the United States, according to a new study published in CHEST.

The Healio editors have compiled a list of the most-read news on interstitial lung diseases published in 2020.

The need for anticoagulation in patients with interstitial lung disease is associated with an increased risk for death and transplant, according to findings published in Chest.

Right inferior pulmonary vein diameter and left ventricular short axis diameter at diagnosis are associated with development of pulmonary hypertension development in patients with combined pulmonary fibrosis and emphysema.